Skip to main content
SpringerLink
Log in

Phase II trial of piroxantrone in gastric carcinoma

A Southwest Oncology Group study

  • Phase II Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Twenty-one evaluable patients with advanced gastric adenocarcinoma were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. One objective response was seen for an overall response rate of 5% (95% confidence interval 0–24%). Toxicities of grade ≥ 3 were primarily hematologie and seen in 13/21 patients. Piroxantrone has minimal activity against gastric adenocarcinoma and no further investigation of this agent on this schedule in this disease is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994. Ca 44:7–26, 1994

    Google Scholar 

  2. Panettiere FJ, Haas C, McDonald B, Costanzi JJ, Talley RW, Athens J, Oishi N, Heilbrun LK, Chen TT: Drug combinations in the treatment of gastric adenocarcinoma. A randomized Southwest Oncology Group study. J Clin Oncol 2:420–424, 1984

    Google Scholar 

  3. Showalter H, Johnson J, Werbel LM, Leopold R, Jackson RC, Elslager EL: 5-[(aminoalkyl)amino] substituted anthra[1,9-cd]pyrazol-6(2h)-ones as novel anticancer agents. Synthesis and biological evaluations. J Med Chem 27:253–255, 1984

    Google Scholar 

  4. Leopold W, Nelson J, Plowman J, Jackson RC: Anthrapyrazoles, a new class of intercalating agents against murine tumors. Cancer Res 45:5532–5539, 1985

    Google Scholar 

  5. Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire WP, Ettinger DS, Noe DA, Grochow LB: Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. Cancer Res 50:3284–3288, 1990

    Google Scholar 

  6. Green S, Weiss G: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Inv New Drugs 10:239–253, 1992

    Google Scholar 

  7. Jenkins TR, Tangen C, Macdonald JS, Weiss G, Chapman R, Hantel A: A phase II trial of piroxantrone in adeno-carcinoma of the pancreas: A Southwest Oncology Group study. Inv New Drugs 11:329–331, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Loyola University Stritch School of Medicine, Maywood, IL

    Alexander Hantel

  2. Southwest Oncology Group Statistical Center, Seattle, WA

    Catherine Tangen

  3. Greenville Cancer Center, Greenville, SC

    William L. Gluck

  4. Temple University, Philadelphia, PA, USA

    John S. Macdonald

Authors
  1. Alexander Hantel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine Tangen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William L. Gluck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John S. Macdonald
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hantel, A., Tangen, C., Gluck, W.L. et al. Phase II trial of piroxantrone in gastric carcinoma. Invest New Drugs 12, 159–161 (1994). https://doi.org/10.1007/BF00874449

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00874449

Key words

Search

Navigation